Zadok D, Haviv D, Vishnevskia-Dai V, Morad Y, Levy Y, Krakowski D, Nemet P
Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel.
Ophthalmology. 1998 Apr;105(4):620-3. doi: 10.1016/S0161-6420(98)94014-3.
To study the efficacy of photoastigmatic refractive keratectomy (PARK) by the MEL 60 (Aesculap-Meditec, Jana, Germany) scanning excimer laser for the treatment of myopic astigmatism, with follow-up of 18 months.
One hundred and twenty-eight eyes of 102 patients with different degrees of myopic astigmatism were treated by PARK and followed prospectively in an open study. Ablations were performed with an MEL 60 excimer laser using an astigmatic module.
Mean preoperative refractive cylinder improved from a preoperative value of -1.8 +/- 0.8 diopters (D; range, -1.0 to -6.0 D) to -0.3 +/- 0.5 D (range, +1.0 to -2.5 D) at 18 months. The mean reduction in cylindrical correction alone was 84 +/- 37% in the low astigmatism group (-1.0 to -1.5 D); 91 +/- 21% in the moderate astigmatism group (-1.75 to -2.5 D); and 75 +/- 25% in the high astigmatism group (-2.75 to -6.0 D). One hundred and three eyes (80%) at 12 months and 100 eyes (85%) at 18 months were within +/-0.5 D of the intended astigmatic correction, with more eyes in the low astigmatic group. One hundred and nineteen eyes (93%) and 114 eyes (97%) at 12 and 18 months, respectively, were within +/-1.0 D of the intended correction. Ninety-two percent to 95.7% of the eyes in the different groups had a postoperative axis less than 10 degrees of the preoperative and intended axis at 12 and 18 months after PARK. Uncorrected visual acuity (UCVA) of 20/40 or better was achieved in nearly 84% of the eyes 12 and 18 months after PARK. A UCVA of 20/20 was achieved in 49% of eyes 18 months after PARK. Ten eyes (8%) underwent reoperation at the end of 12 months.
The data indicate that PARK is an effective surgical tool for correcting astigmatism, especially astigmatism of 1.0 to -2.5 D, with a success rate of approximately 70%.
研究德国耶拿蛇牌美迪泰克公司生产的MEL 60扫描准分子激光进行像散性屈光性角膜切除术(PARK)治疗近视散光的疗效,并进行18个月的随访。
102例不同程度近视散光患者的128只眼接受了PARK治疗,并在一项开放性研究中进行前瞻性随访。使用MEL 60准分子激光散光模块进行消融。
术前平均屈光柱镜度从术前的-1.8±0.8屈光度(D;范围,-1.0至-6.0 D)改善至18个月时的-0.3±0.5 D(范围,+1.0至-2.5 D)。单纯柱镜矫正的平均降低幅度在低散光组(-1.0至-1.5 D)为84±37%;中度散光组(-1.75至-2.5 D)为91±21%;高度散光组(-2.75至-6.0 D)为75±25%。12个月时103只眼(80%)、18个月时100只眼(85%)达到预期散光矫正的±0.5 D范围内,低散光组的眼数更多。12个月时119只眼(93%)、18个月时114只眼(97%)达到预期矫正的±1.0 D范围内。在PARK术后12个月和18个月,不同组中92%至95.7%的眼术后轴位与术前及预期轴位相差小于10度。近84%的眼在PARK术后12个月和18个月时未矫正视力(UCVA)达到20/40或更好。PARK术后18个月时49%的眼UCVA达到20/20。12个月结束时10只眼(8%)接受了再次手术。
数据表明PARK是矫正散光,尤其是1.0至-2.5 D散光的有效手术工具,成功率约为70%。